Zai Lab Announces Participation in March Investor Conferences Read more about Zai Lab Announces Participation in March Investor Conferences
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress Read more about Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA Read more about Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023 Read more about Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Zai Lab Announces Participation in February Investor Conferences Read more about Zai Lab Announces Participation in February Investor Conferences
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA Read more about Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
SEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act Read more about SEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List Read more about Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Zai Lab Appoints Michel Vounatsos To Its Board of Directors Read more about Zai Lab Appoints Michel Vounatsos To Its Board of Directors
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint Read more about Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint